Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration

Anja Ehrhardt1, Jeffrey A Engler, Hui Xu

  • 1Department of Pediatrics, School of Medicine, Stanford University, Stanford, CA 94305, USA. ehrhardt@mvp.uni-muenchen.de

Human Gene Therapy
|October 31, 2006
PubMed

Insights

Gene therapy vectors using phiC31 integrase can cause chromosomal translocations in human cells. This occurs when the integrase recombines with cryptic sites, leading to unintended genetic rearrangements and potential safety concerns.

Area of Science:

  • Genetics
  • Molecular Biology
  • Gene Therapy

Background:

  • Insertional mutagenesis from gene therapy vectors raises safety concerns.
  • PhiC31 integrase mediates site-specific integration via attB and pseudoattP sites.
  • Previous studies focused on targeted integration, not unintended consequences.

Purpose of the Study:

  • To investigate if cryptic phiC31 recognition sites can cause chromosomal rearrangements.
  • To assess the risk of genetic manipulation in somatic cells using phiC31 integrase.

Main Methods:

  • Analysis of 69 independent integration events in human cells.
  • Polymerase chain reaction (PCR) to analyze flanking chromosomal DNA.
  • Genotyping of single-cell clones to confirm translocations.

Main Results:

  • 6 (8.7%) integrations occurred on chromosome 19 (19q13.31).
  • 10 (14.49%) integrations occurred on chromosome 12 (12q22).
  • 15% of integration sites showed transgenes flanked by DNA from different chromosomes, indicating translocations.

Conclusions:

  • Cryptic phiC31 recognition sites in the host genome can lead to chromosomal translocations.
  • The mechanism involves recombination between transgene-flanking and genomic cryptic phiC31 sites.
  • Further characterization of the translocation mechanism is necessary for gene therapy safety.